Literature DB >> 22402331

Disrupted GABAAR trafficking and synaptic inhibition in a mouse model of Huntington's disease.

Eunice Y Yuen1, Jing Wei, Ping Zhong, Zhen Yan.   

Abstract

Growing evidence suggests that Huntington's disease (HD), a neurodegenerative movement disorder caused by the mutant huntingtin (htt) with an expanded polyglutamine (polyQ) repeat, is associated with the altered intracellular trafficking and synaptic function. GABA(A) receptors, the key determinant of the strength of synaptic inhibition, have been found to bind to the huntingtin associated protein 1 (HAP1). HAP1 serves as an adaptor linking GABA(A) receptors to the kinesin family motor protein 5 (KIF5), controlling the transport of GABA(A) receptors along microtubules in dendrites. In this study, we found that GABA(A)R-mediated synaptic transmission is significantly impaired in a transgenic mouse model of HD expressing polyQ-htt, which is accompanied by the diminished surface expression of GABA(A) receptors. Moreover, the GABA(A)R/HAP1/KIF5 complex is disrupted and dissociated from microtubules in the HD mouse model. These results suggest that GABA(A)R trafficking and function is impaired in HD, presumably due to the interference of KIF5-mediated microtubule-based transport of GABA(A) receptors. The diminished inhibitory synaptic efficacy could contribute to the loss of the excitatory/inhibitory balance, leading to increased neuronal excitotoxicity in HD.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22402331      PMCID: PMC3323696          DOI: 10.1016/j.nbd.2012.02.015

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  43 in total

Review 1.  HAP1 and intracellular trafficking.

Authors:  Xiao-Jiang Li; Shi-Hua Li
Journal:  Trends Pharmacol Sci       Date:  2005-01       Impact factor: 14.819

2.  Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice.

Authors:  Xiaofeng Gu; Chenjian Li; Weizheng Wei; Victor Lo; Shiaoching Gong; Shi-Hua Li; Takuji Iwasato; Shigeyoshi Itohara; Xiao-Jiang Li; Istvan Mody; Nathaniel Heintz; X William Yang
Journal:  Neuron       Date:  2005-05-05       Impact factor: 17.173

Review 3.  Synaptic dysfunction in Huntington's disease: a new perspective.

Authors:  R Smith; P Brundin; J-Y Li
Journal:  Cell Mol Life Sci       Date:  2005-09       Impact factor: 9.261

Review 4.  Huntington disease.

Authors:  J P Vonsattel; M DiFiglia
Journal:  J Neuropathol Exp Neurol       Date:  1998-05       Impact factor: 3.685

5.  Interaction of Huntingtin-associated protein-1 with kinesin light chain: implications in intracellular trafficking in neurons.

Authors:  John Russel McGuire; Juan Rong; Shi-Hua Li; Xiao-Jiang Li
Journal:  J Biol Chem       Date:  2005-12-08       Impact factor: 5.157

6.  Increased GABAergic function in mouse models of Huntington's disease: reversal by BDNF.

Authors:  Carlos Cepeda; Amaal J Starling; Nanping Wu; Oanh K Nguyen; Besim Uzgil; Takahiro Soda; Veronique M André; Marjorie A Ariano; Michael S Levine
Journal:  J Neurosci Res       Date:  2004-12-15       Impact factor: 4.164

7.  D5 dopamine receptors enhance Zn2+-sensitive GABA(A) currents in striatal cholinergic interneurons through a PKA/PP1 cascade.

Authors:  Z Yan; D J Surmeier
Journal:  Neuron       Date:  1997-11       Impact factor: 17.173

8.  Huntingtin-associated protein 1 (HAP1) interacts with the p150Glued subunit of dynactin.

Authors:  S Engelender; A H Sharp; V Colomer; M K Tokito; A Lanahan; P Worley; E L Holzbaur; C A Ross
Journal:  Hum Mol Genet       Date:  1997-12       Impact factor: 6.150

9.  Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin.

Authors:  G Schilling; M W Becher; A H Sharp; H A Jinnah; K Duan; J A Kotzuk; H H Slunt; T Ratovitski; J K Cooper; N A Jenkins; N G Copeland; D L Price; C A Ross; D R Borchelt
Journal:  Hum Mol Genet       Date:  1999-03       Impact factor: 6.150

10.  Abnormal sensitivity to cannabinoid receptor stimulation might contribute to altered gamma-aminobutyric acid transmission in the striatum of R6/2 Huntington's disease mice.

Authors:  Diego Centonze; Silvia Rossi; Chiara Prosperetti; Anne Tscherter; Giorgio Bernardi; Mauro Maccarrone; Paolo Calabresi
Journal:  Biol Psychiatry       Date:  2005-06-15       Impact factor: 13.382

View more
  11 in total

Review 1.  Alteration of GABAergic neurotransmission in Huntington's disease.

Authors:  Maurice Garret; Zhuowei Du; Marine Chazalon; Yoon H Cho; Jérôme Baufreton
Journal:  CNS Neurosci Ther       Date:  2018-02-21       Impact factor: 5.243

2.  DISC1 Protein Regulates γ-Aminobutyric Acid, Type A (GABAA) Receptor Trafficking and Inhibitory Synaptic Transmission in Cortical Neurons.

Authors:  Jing Wei; Nicholas M Graziane; Zhenglin Gu; Zhen Yan
Journal:  J Biol Chem       Date:  2015-09-30       Impact factor: 5.157

3.  The Anaphase-Promoting Complex (APC) ubiquitin ligase regulates GABA transmission at the C. elegans neuromuscular junction.

Authors:  Jennifer R Kowalski; Hitesh Dube; Denis Touroutine; Kristen M Rush; Patricia R Goodwin; Marc Carozza; Zachary Didier; Michael M Francis; Peter Juo
Journal:  Mol Cell Neurosci       Date:  2013-12-07       Impact factor: 4.314

4.  Postnatal and adult consequences of loss of huntingtin during development: Implications for Huntington's disease.

Authors:  Eduardo E Arteaga-Bracho; Maria Gulinello; Michael L Winchester; Nandini Pichamoorthy; Jenna R Petronglo; Alicia D Zambrano; Julio Inocencio; Chirstopher D De Jesus; Joseph O Louie; Solen Gokhan; Mark F Mehler; Aldrin E Molero
Journal:  Neurobiol Dis       Date:  2016-09-10       Impact factor: 5.996

5.  Multiple sources of striatal inhibition are differentially affected in Huntington's disease mouse models.

Authors:  Carlos Cepeda; Laurie Galvan; Sandra M Holley; Shilpa P Rao; Véronique M André; Elian P Botelho; Jane Y Chen; Joseph B Watson; Karl Deisseroth; Michael S Levine
Journal:  J Neurosci       Date:  2013-04-24       Impact factor: 6.167

6.  Beyond the redox imbalance: Oxidative stress contributes to an impaired GLUT3 modulation in Huntington's disease.

Authors:  Adriana Covarrubias-Pinto; Pablo Moll; Macarena Solís-Maldonado; Aníbal I Acuña; Andrea Riveros; María Paz Miró; Eduardo Papic; Felipe A Beltrán; Carlos Cepeda; Ilona I Concha; Sebastián Brauchi; Maite A Castro
Journal:  Free Radic Biol Med       Date:  2015-10-09       Impact factor: 7.376

7.  HAP1 Modulates Epileptic Seizures by Regulating GABAAR Function in Patients with Temporal Lobe Epilepsy and in the PTZ-Induced Epileptic Model.

Authors:  Rong Li; Bing Wu; Miaoqing He; Peng Zhang; Qinbin Zhang; Jing Deng; Jinxian Yuan; Yangmei Chen
Journal:  Neurochem Res       Date:  2020-05-17       Impact factor: 3.996

Review 8.  Mood disorders in Huntington's disease: from behavior to cellular and molecular mechanisms.

Authors:  Patrick Pla; Sophie Orvoen; Frédéric Saudou; Denis J David; Sandrine Humbert
Journal:  Front Behav Neurosci       Date:  2014-04-23       Impact factor: 3.558

Review 9.  Huntington's Disease: Mechanisms of Pathogenesis and Therapeutic Strategies.

Authors:  Maria Jimenez-Sanchez; Floriana Licitra; Benjamin R Underwood; David C Rubinsztein
Journal:  Cold Spring Harb Perspect Med       Date:  2017-07-05       Impact factor: 6.915

Review 10.  Mouse models of polyglutamine diseases: review and data table. Part I.

Authors:  Maciej Figiel; Wojciech J Szlachcic; Pawel M Switonski; Agnieszka Gabka; Wlodzimierz J Krzyzosiak
Journal:  Mol Neurobiol       Date:  2012-09-07       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.